Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-2173 and Vebicorvir with TDF in Chronic Hepatitis B
NCT05238844Phase 2Terminated
- Sponsor
- Antios Therapeutics
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ATI-2173 and vebicorvir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Antios Therapeutics. Primary endpoints: Treatment-emergent adverse events at 1 year, Treatment-emergent serious adverse events at 1 year and 5 more. Started Apr 2022; status: terminated.
02
Drugs
ATI-2173vebicorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05238844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238844.